About Michael Hamblin. Dr. Hamblin is a Principal Investigator at the Wellman Center for Photomedicine at Massachusetts General Hospital, an Associate Professor of Dermatology at Harvard Medical School and is a member of the affiliated faculty of the Harvard-MIT Division of Health Science and Technology. He was trained as a synthetic organic chemist and received his Ph.D. from Trent University in England. His research interests lie in the areas of photodynamic therapy (PDT) for infections, cancer, and stimulation of the immune system, and in photobiomodulation or low-level light therapy (LLLT) for wound healing, arthritis, traumatic brain injury, neurodegenerative diseases and psychiatric disorders. He directs a laboratory of around a dozen post-doctoral fellows, visiting scientists and graduate students. His research program is supported by NIH, CDMRP, USAFOSR, and CIMIT among other funding agencies. He has published over 320 peer-reviewed articles, over 150 conference proceedings, book chapters and International abstracts and holds 10 patents. He is an associate editor for 8 journals, serves on the editorial board of an additional 30 journals, and also serves on NIH Study Sections. For the past 11 years, Dr. Hamblin has chaired an annual conference at SPIE Photonics West entitled "Mechanisms for low level light therapy" and he has edited the 11 proceedings volumes together with 6 other major textbooks on PDT and photomedicine. He has several other book projects in progress at various stages of completion. In 2011, Dr Hamblin was honored by election as a Fellow of SPIE. He is a Visiting Professor at universities in China, South Africa, and Northern Ireland.